Since the entry into force of the revised therapeutic products legislation on 1 January 2019, Swissmedic has published summarised assessment reports, known as the “Swiss Public Assessment Report” (SwissPAR for short). In addition, Swissmedic publishes a short version that is understandable to lay people: the “Summary report on authorisation”. This was previously known as the “Public Summary SwissPAR”.
The content of the Summary report on authorisation is unchanged and will continue to make Swissmedic's authorisation decisions comprehensible and transparent to the wider public.
The guidance document SwissPAR has been revised accordingly.
The revised guidance document SwissPAR enters into force on 1 October 2024.